QUATTRO IN ACTION
INTERVENTIONAL NEURORADIOLOGY + ENDOVASCULAR NEUROSURGERY
Among many possible growth paths, what should the company prioritize to maximize overall company value?
NEW CEO OF THE LEADING MAKER OF NEUROVASCULAR MICROCATHETERS
A new CEO had been appointed by the Board to lead a company with a promising array of neurovascular microcatheters as well as other endovascular neurosurgery products including coils and stents.
The CEO and senior team were undecided about which of several alternative growth strategy options to choose since pursuing all was not financially feasible. The CEO selected Quattro to assist in the choice.
Building from detailed procedure-specific feedback from physicians, Quattro created a cutting-edge market model to size the company’s opportunities.
The model incorporated core competitive advantages and weaknesses, physician perceptions and potential usage, as well as incident and prevalent populations and growth rates. Quattro identified an unexpected growth opportunity and proposed a strategy targeting one particularly dangerous neurovascular condition, emphasizing the company’s novel coil with the microcatheter in a supporting role.
Market model and growth strategy increased shareholder value over $500MM and helped drive the largest medtech acquisition premium of the year.
Quattro worked closely with the CEO and senior management team over two years as the team adopted, learned, refined, and fully implemented the new growth strategy.
Following the initial development, Quattro also worked closely with functional and cross-functional teams on comprehensive change management. The company developed an exceptional reputation as the leader in its rapidly growing specialized medical device arena.
It was eventually acquired by the broad market leader in catheters. The premium paid for Quattro’s client was one of the largest of the year among all medical device transactions.